PEDMARK integration reported in head and neck cancer care

An article from Fennec Pharmaceuticals reports that PEDMARK given about six hours after cisplatin was safe and could be integrated into care for adults with head and neck cancers, and early data showed signals of hearing preservation without apparent interference with cisplatin's antitumor activity.

The article presents real-world data about PEDMARK use in adults with head and neck cancers. It reports that administering PEDMARK approximately six hours after cisplatin was safe and could be integrated into clinical care. The article also describes early signals of hearing preservation. It states that these signals did not appear to compromise cisplatin's established antitumor activity. Key points: - PEDMARK was administered about six hours after cisplatin in adults with head and neck cancers. - The timing was reported as safe and feasible to integrate into routine care. - Early signals of hearing preservation were described in the reported data. - The article indicates cisplatin's antitumor activity was not compromised in the presented observations. - The findings are presented as real-world data from the reporting organization. Summary: The article describes real-world observations that PEDMARK can be given approximately six hours after cisplatin with manageable integration into care and early indications of hearing preservation while reporting no apparent interference with cisplatin's antitumor effects. Undetermined at this time.